arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2024-2380AWGRWKarthyper-2380Research ArticleСтатьиArticlesКлиническое значение вазореактивности у пациентов с легочной артериальной гипертензией: новый взгляд на хорошо забытоеClinical significance of vasoreactivity in patients with pulmonary arterial hypertension: a new glancehttps://orcid.org/0000-0001-6954-7096ГончароваН. С.GoncharovaN. S.

Гончарова Наталья Сергеевна — кандидат медицинских наук, старший научный сотрудник научно-исследовательского отдела «Некоронарогенные заболевания сердца» 

ул. Аккуратова, д. 2, Санкт-Петербург, 197341

Natalia S. Goncharova, MD, PhD, Senior Researcher, Noncoronary Disease Department

2 Akkuratov str., St Petersburg, 197341 

ns.goncharova@gmail.comhttps://orcid.org/0000-0002-7337-0972ЛапшинК. Б.LapshinK. B.

Лапшин Кирилл Борисович — заведующий отделением анестезиологии-реанимации с палатами реанимации и интенсивной терапии 

Санкт-Петербург

Kirill B. Lapshin, MD, Head, Intensive Care Unit Department

St Petersburg

lapshinkb@gmail.comhttps://orcid.org/0009-0007-7398-2948МатакаеваЖ. А.MatakaevaZh. A.

Матакаева Жанета Альбековна — заведующая отделением анестезиологии и реанимации с палатами интенсивной терапии 

Санкт-Петербург

Zhaneta A. Matakaeva, MD, Head, Intensive Care Unit Department

St Petersburg

matakaeva_zha@almazovcentre.ruhttps://orcid.org/0000-0001-6081-1559АндрееваЕ. М.AndreevaE. M.

Андреева Елизавета Михайловна — лаборант-исследователь научно-исследовательской лаборатории соединительнотканных дисплазий научно-исследовательского отдела «Некоронарогенные заболевания сердца» 

Санкт-Петербург

Elizaveta M. Andreeva, MD, Assistant Researcher, Noncoronary Disease Department

St Petersburg

elizaa.andreeva@gmail.comhttps://orcid.org/0000-0002-7817-3847МоисееваО. М.MoiseevaO. M.

Моисеева Ольга Михайловна — доктор медицинских наук, профессор, заведующая научно-исследовательским отделом «Некоронарогенные заболевания сердца», директор Института сердца и сосудов 

Санкт-Петербург

Olga M. Moiseeva, MD, PhD, Associate Professor, Head, Heart and Vessels Institute, Head, Noncoronary Disease Department

St Petersburg

moiseeva.cardio@gmail.comФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской ФедерацииРоссияAlmazov National Medical Research CenterRussian Federation202425032024302174184Copyright © Гончарова Н.С., Лапшин К.Б., Матакаева Ж.А., Андреева Е.М., Моисеева О.М., 20242024Гончарова Н.С., Лапшин К.Б., Матакаева Ж.А., Андреева Е.М., Моисеева О.М.Goncharova N.S., Lapshin K.B., Matakaeva Z.A., Andreeva E.M., Moiseeva O.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/2380

Длительные респондеры к терапии блокаторами кальциевых каналов (БКК) являются минорной группой среди пациентов с идиопатической/наследственной/лекарственной легочной артериальной гипертензией (ЛАГ). С широким внедрением специфических препаратов для лечения ЛАГ частота выполнения вазореактивного теста (ВРТ), необходимого для определения возможности назначения БКК, значительно сократилась. Настоящая статья освещает современные представления о морфофункциональных особенностях сосудов малого круга кровообращения, генетики у пациентов с длительным ответом на терапию БКК. Приводятся данные о частоте выполнения ВРТ в популяции пациентов с идиопатической ЛАГ. Обсуждаются перспективы использования вазореактивного резерва для оценки прогноза и ответа на ЛАГ-специфическую терапию.

Long-term responders for calcium channel blocker (CCB) therapy represent the minority population among the patients with idiopathic/hereditary/drug-induced pulmonary arterial hypertension (PAH). The frequency of vasoreactive testing (VRT) has been dramatically decreased over the past decade in clinical practice, while the amount of PAH specific therapy prescription has been raised substantially. Current review highlights the frequency of VRT in the modern population of patients with idiopathic PAH. Interconnections between pulmonary vascular morphology, physiology and genetics in long-term responders for CCB therapy and patients with negative VRT are analyzed. Pulmonary vasoreactive reserve prognostic value discussed.

вазореактивный тестидиопатическая легочная артериальная гипертензиявазореактивный резерввыживаемостьvasoreactive testidiopathic pulmonary arterial hypertensionvasoreactive reservesurvivalГрант Российского научного фонда, соглашение № 23–15–00–318Grant from the Russian Science Foundation, agreement No. 23–15–00–318ReferencesSitbon O, Humbert M, Jaïs X, Ioos V, Hamid AM, Provencher S et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111(23):3105–3111. doi:10.1161/CIRCULATIONAHA.104.488486Sitbon O, Humbert M, Jaïs X, Ioos V, Hamid AM, Provencher S et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111(23):3105–3111. doi:10.1161/CIRCULATIONAHA.104.488486Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61(1):2200879. doi:10.1183/13993003.00879-2022Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61(1):2200879. doi:10.1183/13993003.00879-2022Sharma A, Obiagwu C, Mezue K, Garg A, Mukherjee D, Haythe J et al. Role of vasodilator testing in pulmonary hypertension. Prog Cardiovasc Dis. 2016;58(4):425–433. doi:10.1016/j.pcad.2015.09.006Sharma A, Obiagwu C, Mezue K, Garg A, Mukherjee D, Haythe J et al. Role of vasodilator testing in pulmonary hypertension. Prog Cardiovasc Dis. 2016;58(4):425–433. doi:10.1016/j.pcad.2015.09.006Leuchte HH, Schwaiblmair M, Baumgartner RA, Neurohr CF, Kolbe T, Behr J. Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. Chest. 2004;125(2):580–586. doi:10.1378/chest.125.2.580Leuchte HH, Schwaiblmair M, Baumgartner RA, Neurohr CF, Kolbe T, Behr J. Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. Chest. 2004;125(2):580–586. doi:10.1378/chest.125.2.580Montani D, Savale L, Natali D, Jaïs X, Herve P, Garcia G et al. Long-term response to calcium-channel blockers in nonidiopathic pulmonary arterial hypertension. Eur Heart J. 2010; 31(15):1898–1907. doi:10.1093/eurheartj/ehq170Montani D, Savale L, Natali D, Jaïs X, Herve P, Garcia G et al. Long-term response to calcium-channel blockers in nonidiopathic pulmonary arterial hypertension. Eur Heart J. 2010; 31(15):1898–1907. doi:10.1093/eurheartj/ehq170Chandrasekara S, Lau EM, Anderson J, Collins N, Cordina R, Corrigan C et al. Acute vasoreactivity testing and outcomes in pulmonary arterial hypertension: a call for increased testing. Heart Lung Circ. 2023;32(2):156–165. doi:10.1016/j.hlc.2022.09.005Chandrasekara S, Lau EM, Anderson J, Collins N, Cordina R, Corrigan C et al. Acute vasoreactivity testing and outcomes in pulmonary arterial hypertension: a call for increased testing. Heart Lung Circ. 2023;32(2):156–165. doi:10.1016/j.hlc.2022.09.005Rao BNS, Moller JH, Edwards JE. Primary pulmonary hypertension in a child. Response to pharmacologic agents. Circulation. 1969;40(4):583–588. doi:10.1161/01.CIR.40.4.583Rao BNS, Moller JH, Edwards JE. Primary pulmonary hypertension in a child. Response to pharmacologic agents. Circulation. 1969;40(4):583–588. doi:10.1161/01.CIR.40.4.583Palevsky HI, Schloo BL, Pietra GG, Weber KT, Janicki JS, Rubin E et al. Primary pulmonary hypertension. Vascular structure, morphometry, and responsiveness to vasodilator agents. Circulation. 1989;80(5):1207–1221. doi:10.1161/01.cir.80.5.1207Palevsky HI, Schloo BL, Pietra GG, Weber KT, Janicki JS, Rubin E et al. Primary pulmonary hypertension. Vascular structure, morphometry, and responsiveness to vasodilator agents. Circulation. 1989;80(5):1207–1221. doi:10.1161/01.cir.80.5.1207Langleben D, Orfanos S. Vasodilator responsiveness in idiopathic pulmonary arterial hypertension: identifying a distinct phenotype with distinct physiology and distinct prognosis. Pulm Circ. 2017;7(3):588–597. doi:10.1177/2045893217714231Langleben D, Orfanos S. Vasodilator responsiveness in idiopathic pulmonary arterial hypertension: identifying a distinct phenotype with distinct physiology and distinct prognosis. Pulm Circ. 2017;7(3):588–597. doi:10.1177/2045893217714231Langleben D, Orfanos SE, Giovinazzo M, Hirsch A, Baron M, Senécal JL et al. Pulmonary capillary endothelial metabolic dysfunction: severity in pulmonary arterial hypertension related to connective tissue disease versus idiopathic pulmonary arterial hypertension. Arthritis Rheum. 2008;58(4):1156–1164. doi:10.1002/art.23405Langleben D, Orfanos SE, Giovinazzo M, Hirsch A, Baron M, Senécal JL et al. Pulmonary capillary endothelial metabolic dysfunction: severity in pulmonary arterial hypertension related to connective tissue disease versus idiopathic pulmonary arterial hypertension. Arthritis Rheum. 2008;58(4):1156–1164. doi:10.1002/art.23405Harel F, Langleben D, Provencher S, Fournier A, Finnerty V, Nguyen QT et al. Molecular imaging of the human pulmonary vascular endothelium in pulmonary hypertension: a phase II safety and proof of principle trial. Eur J Nucl Med Mol Imaging. 2017;44(7):1136–1144. doi:10.1007/s00259-017-3655-yHarel F, Langleben D, Provencher S, Fournier A, Finnerty V, Nguyen QT et al. Molecular imaging of the human pulmonary vascular endothelium in pulmonary hypertension: a phase II safety and proof of principle trial. Eur J Nucl Med Mol Imaging. 2017;44(7):1136–1144. doi:10.1007/s00259-017-3655-yStacher E, Graham BB, Hunt JM, Gandjeva A, Groshong SD, McLaughlin VV et al. Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012; 186(3):261–272. doi:10.1164/rccm.201201-0164OCStacher E, Graham BB, Hunt JM, Gandjeva A, Groshong SD, McLaughlin VV et al. Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012; 186(3):261–272. doi:10.1164/rccm.201201-0164OCHemnes AR, Zhao M, West J, Newman JH, Rich S, Archer SL et al. Critical genomic networks and vasoreactive variants in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2016;194(4):464–475. doi:10.1164/rccm.201508-1678OCHemnes AR, Zhao M, West J, Newman JH, Rich S, Archer SL et al. Critical genomic networks and vasoreactive variants in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2016;194(4):464–475. doi:10.1164/rccm.201508-1678OCHemnes AR, Trammell AW, Archer SL, Rich S, Yu C, Nian H et al. Peripheral blood signature of vasodilator-responsive pulmonary arterial hypertension. Circulation. 2015;131(4):401–409; discussion 409. doi:10.1161/CIRCULATIONAHA.114.013317Hemnes AR, Trammell AW, Archer SL, Rich S, Yu C, Nian H et al. Peripheral blood signature of vasodilator-responsive pulmonary arterial hypertension. Circulation. 2015;131(4):401–409; discussion 409. doi:10.1161/CIRCULATIONAHA.114.013317Renard S, Paulin R, Breuils-Bonnet S, Simard S, Pibarot P, Bonnet S et al. Pim 1: a new biomarker in pulmonary arterial hypertension. Pulm Circ. 2013;3(1):74–81. doi:10.4103/2045-8932.109917Renard S, Paulin R, Breuils-Bonnet S, Simard S, Pibarot P, Bonnet S et al. Pim 1: a new biomarker in pulmonary arterial hypertension. Pulm Circ. 2013;3(1):74–81. doi:10.4103/2045-8932.109917Benza RL, Gomberg-Maitland M, Elliott CG, Farber HW, Foreman AJ, Frost AE et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. Chest. 2019;156(2):323–337. doi:10.1016/j.chest.2019.02.004Benza RL, Gomberg-Maitland M, Elliott CG, Farber HW, Foreman AJ, Frost AE et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. Chest. 2019;156(2):323–337. doi:10.1016/j.chest.2019.02.004Reeves JT, Groves BM, Turkevich D. The case for treatment of selected patients with primary pulmonary hypertension. Am Rev Respir Dis. 1986;134(2):342–346. doi:10.1164/arrd.1986.134.2.342Reeves JT, Groves BM, Turkevich D. The case for treatment of selected patients with primary pulmonary hypertension. Am Rev Respir Dis. 1986;134(2):342–346. doi:10.1164/arrd.1986.134.2.342D’Alto M, Badagliacca R, Argiento P, Romeo E, Farro A, Papa S et al. Risk reduction and right heart reverse remodeling by upfront triple combination therapy in pulmonary arterial hypertension. Chest. 2020;157(2):376–383. doi:10.1016/j.chest.2019.09.009D’Alto M, Badagliacca R, Argiento P, Romeo E, Farro A, Papa S et al. Risk reduction and right heart reverse remodeling by upfront triple combination therapy in pulmonary arterial hypertension. Chest. 2020;157(2):376–383. doi:10.1016/j.chest.2019.09.009D’Alto M, Badagliacca R, Lo Giudice F, Argiento P, Casu G, Corda M et al. Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan‒tadalafil in pulmonary arterial hypertension. J Heart Lung Transplant. 2020;39(12):1389–1397. doi:10.1016/j.healun.2020.08.016D’Alto M, Badagliacca R, Lo Giudice F, Argiento P, Casu G, Corda M et al. Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan‒tadalafil in pulmonary arterial hypertension. J Heart Lung Transplant. 2020;39(12):1389–1397. doi:10.1016/j.healun.2020.08.016Badagliacca R, Manzi G, Vizza CD. Right-heart reverse remodeling during treatment for pulmonary hypertension. In: Gaine SP, Naeije R, Peacock AJ ed. The right heart. Cham: Springer International Publishing; 2021. P. 291–299. doi:10.1007/978-3-030-78255-9_16Badagliacca R, Manzi G, Vizza CD. Right-heart reverse remodeling during treatment for pulmonary hypertension. In: Gaine SP, Naeije R, Peacock AJ ed. The right heart. Cham: Springer International Publishing; 2021. P. 291–299. doi:10.1007/978-3-030-78255-9_16Badagliacca R, D’Alto M, Ghio S, Argiento P, Brunetti ND, Casu G et al. Relevance of comorbidities on initial combination therapy in pulmonary arterial hypertension. ERJ Open Res. 2022; 8(4):00298–02022. doi:10.1183/23120541.00298-2022Badagliacca R, D’Alto M, Ghio S, Argiento P, Brunetti ND, Casu G et al. Relevance of comorbidities on initial combination therapy in pulmonary arterial hypertension. ERJ Open Res. 2022; 8(4):00298–02022. doi:10.1183/23120541.00298-2022Kemp K, Savale L, O’Callaghan DS, Jaïs X, Montani D, Humbert M et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. J Heart Lung Transplantat. 2012;31(2):150– 158. doi:10.1016/j.healun.2011.11.002Kemp K, Savale L, O’Callaghan DS, Jaïs X, Montani D, Humbert M et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. J Heart Lung Transplantat. 2012;31(2):150– 158. doi:10.1016/j.healun.2011.11.002Sitbon O, Jaïs X, Savale L, Cottin V, Bergot E, Macari EA et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J. 2014;43(6):1691–1697. doi:10.1183/09031936.00116313Sitbon O, Jaïs X, Savale L, Cottin V, Bergot E, Macari EA et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J. 2014;43(6):1691–1697. doi:10.1183/09031936.00116313Boucly A, Savale L, Jaïs X, Bauer F, Bergot E, Bertoletti L et al. Association between initial treatment strategy and long-term survival in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2021;204(7):842–854. doi:10.1164/rccm.202009-3698OCBoucly A, Savale L, Jaïs X, Bauer F, Bergot E, Bertoletti L et al. Association between initial treatment strategy and long-term survival in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2021;204(7):842–854. doi:10.1164/rccm.202009-3698OCvan de Veerdonk MC, Kind T, Marcus JT, Mauritz GJ, Heymans MW, Bogaard HJ et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol. 2011;58(24):2511–2519. doi:10.1016/j.jacc.2011.06.068van de Veerdonk MC, Kind T, Marcus JT, Mauritz GJ, Heymans MW, Bogaard HJ et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol. 2011;58(24):2511–2519. doi:10.1016/j.jacc.2011.06.068Badagliacca R, D’Alto M, Ghio S, Argiento P, Bellomo V, Brunetti ND et al. Risk Reduction and hemodynamics with initial combination therapy in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2021;203(4):484–492. doi:10.1164/rccm.202004-1006OCBadagliacca R, D’Alto M, Ghio S, Argiento P, Bellomo V, Brunetti ND et al. Risk Reduction and hemodynamics with initial combination therapy in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2021;203(4):484–492. doi:10.1164/rccm.202004-1006OCMalhotra R, Hess D, Lewis GD, Bloch KD, Waxman AB, Semigran MJ. Vasoreactivity to inhaled nitric oxide with oxygen predicts long-term survival in pulmonary arterial hypertension. Pulm Circ. 2011;1(2):250–258. doi:10.4103/2045-8932.83449Malhotra R, Hess D, Lewis GD, Bloch KD, Waxman AB, Semigran MJ. Vasoreactivity to inhaled nitric oxide with oxygen predicts long-term survival in pulmonary arterial hypertension. Pulm Circ. 2011;1(2):250–258. doi:10.4103/2045-8932.83449Leuchte HH, Baezner C, Baumgartner RA, Muehling O, Neurohr C, Behr J. Residual pulmonary vasodilative reserve predicts outcome in idiopathic pulmonary hypertension. Heart. 2015;101(12):972–976. doi:10.1136/heartjnl-2015-307529Leuchte HH, Baezner C, Baumgartner RA, Muehling O, Neurohr C, Behr J. Residual pulmonary vasodilative reserve predicts outcome in idiopathic pulmonary hypertension. Heart. 2015;101(12):972–976. doi:10.1136/heartjnl-2015-307529Sun Y, Li Y, Meng X, Jiang R, Zhao Q, Wang L et al. Acute vasoreactivity testing predicts outcome of idiopathic pulmonary arterial hypertension patients with a negative acute response. Ann Transl Med. 2020;8(24):1650. doi:10.21037/atm-20-7339Sun Y, Li Y, Meng X, Jiang R, Zhao Q, Wang L et al. Acute vasoreactivity testing predicts outcome of idiopathic pulmonary arterial hypertension patients with a negative acute response. Ann Transl Med. 2020;8(24):1650. doi:10.21037/atm-20-7339Naranjo M, Rosenzweig EB, Hemnes AR, Jacob M, Desai A, Hill NS et al. Frequency of acute vasodilator response (AVR) in incident and prevalent patients with pulmonary arterial hypertension: Results from the pulmonary vascular disease phenomics study. Pulm Circ. 2023;13(3): e12281. doi:10.1002/pul2.12281Naranjo M, Rosenzweig EB, Hemnes AR, Jacob M, Desai A, Hill NS et al. Frequency of acute vasodilator response (AVR) in incident and prevalent patients with pulmonary arterial hypertension: Results from the pulmonary vascular disease phenomics study. Pulm Circ. 2023;13(3): e12281. doi:10.1002/pul2.12281Tonelli AR, Alnuaimat H, Mubarak K. Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension. Respir Med. 2010;104(4):481–496. doi:10.1016/j.rmed.2009.11.015Tonelli AR, Alnuaimat H, Mubarak K. Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension. Respir Med. 2010;104(4):481–496. doi:10.1016/j.rmed.2009.11.015Liu YT, Li MT, Fang Q, Tian Z, Guo XX, Zhu WL et al. Right-heart function related to the results of acute pulmonary vasodilator testing in patients with pulmonary arterial hypertension caused by connective tissue disease. J Am Soc Echocardiogr. 2012;25(3):274–279. doi:10.1016/j.echo.2011.11.007Liu YT, Li MT, Fang Q, Tian Z, Guo XX, Zhu WL et al. Right-heart function related to the results of acute pulmonary vasodilator testing in patients with pulmonary arterial hypertension caused by connective tissue disease. J Am Soc Echocardiogr. 2012;25(3):274–279. doi:10.1016/j.echo.2011.11.007

The authors declare that there are no conflicts of interest present.